Market Closed -
Nasdaq
04:00:00 2024-05-13 pm EDT
|
5-day change
|
1st Jan Change
|
4.46
USD
|
-11.68%
|
|
-25.42%
|
+15.54%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
328.5
|
63.03
|
139.7
|
219.4
|
-
|
-
|
Enterprise Value (EV)
1 |
328.5
|
63.03
|
139.7
|
219.4
|
219.4
|
219.4
|
P/E ratio
|
-1.09
x
|
-1.1
x
|
-3.68
x
|
-3.43
x
|
-3.66
x
|
-3.38
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
3.84
x
|
7.01
x
|
118
x
|
18.2
x
|
17.6
x
|
EV / Revenue
|
-
|
3.84
x
|
7.01
x
|
118
x
|
18.2
x
|
17.6
x
|
EV / EBITDA
|
-6.59
x
|
-1.15
x
|
-3.61
x
|
-3.26
x
|
-2.84
x
|
-
|
EV / FCF
|
-7.57
x
|
-1.43
x
|
-4.19
x
|
-3.46
x
|
-4.82
x
|
-4.16
x
|
FCF Yield
|
-13.2%
|
-70.1%
|
-23.9%
|
-28.9%
|
-20.7%
|
-24.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
27,579
|
30,745
|
36,192
|
43,455
|
-
|
-
|
Reference price
2 |
11.91
|
2.050
|
3.860
|
5.050
|
5.050
|
5.050
|
Announcement Date
|
3/24/22
|
3/23/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
16.4
|
19.94
|
1.86
|
12.03
|
12.5
|
EBITDA
1 |
-
|
-49.87
|
-54.95
|
-38.74
|
-67.36
|
-77.32
|
-
|
EBIT
1 |
-22.4
|
-50.09
|
-56.06
|
-40.5
|
-70.63
|
-71.56
|
-86.54
|
Operating Margin
|
-
|
-
|
-341.78%
|
-203.09%
|
-3,796.1%
|
-594.71%
|
-692.33%
|
Earnings before Tax (EBT)
1 |
-
|
-49.98
|
-53.81
|
-37.37
|
-67.59
|
-66.66
|
-86.68
|
Net income
1 |
-
|
-201.9
|
-53.81
|
-37.37
|
-67.57
|
-68.79
|
-86.68
|
Net margin
|
-
|
-
|
-328.09%
|
-187.37%
|
-3,632.06%
|
-571.71%
|
-693.44%
|
EPS
2 |
-3.240
|
-10.94
|
-1.860
|
-1.050
|
-1.472
|
-1.380
|
-1.492
|
Free Cash Flow
1 |
-
|
-43.37
|
-44.21
|
-33.38
|
-63.48
|
-45.52
|
-52.78
|
FCF margin
|
-
|
-
|
-269.54%
|
-167.38%
|
-3,411.72%
|
-378.36%
|
-422.24%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/21
|
3/24/22
|
3/23/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
4.148
|
4.97
|
7.283
|
4.464
|
8.081
|
5.897
|
1.501
|
0.742
|
0.5
|
0.5
|
0.5
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3.703
|
-6.709
|
-12.5
|
-
|
-14.37
|
-
|
-
|
-
|
EBIT
1 |
-13.8
|
-17.88
|
-15.37
|
-14.97
|
-12.54
|
-13.18
|
-12.22
|
-6.067
|
-9.251
|
-12.96
|
-17.16
|
-17.14
|
-17.9
|
-18.26
|
-18.84
|
Operating Margin
|
-
|
-
|
-
|
-360.95%
|
-252.29%
|
-180.96%
|
-273.81%
|
-75.08%
|
-156.88%
|
-863.56%
|
-2,312.94%
|
-3,427.85%
|
-3,580.25%
|
-3,652.06%
|
-
|
Earnings before Tax (EBT)
1 |
-13.76
|
-17.87
|
-15.34
|
-14.59
|
-11.94
|
-11.93
|
-11.98
|
-5.098
|
-8.285
|
-12
|
-16.19
|
-16.66
|
-16.81
|
-17.46
|
-15.24
|
Net income
1 |
-13.76
|
-17.87
|
-15.34
|
-14.59
|
-11.94
|
-11.93
|
-11.98
|
-5.098
|
-8.285
|
-12
|
-16.19
|
-16.54
|
-16.98
|
-17.49
|
-15.24
|
Net margin
|
-
|
-
|
-
|
-351.83%
|
-240.3%
|
-163.81%
|
-268.41%
|
-63.09%
|
-140.5%
|
-799.67%
|
-2,182.35%
|
-3,308.2%
|
-3,395.13%
|
-3,498.73%
|
-
|
EPS
2 |
-0.5100
|
-0.6600
|
-0.5600
|
-0.5300
|
-0.4000
|
-0.3900
|
-0.3400
|
-0.1400
|
-0.2300
|
-0.3300
|
-0.3900
|
-0.3660
|
-0.3460
|
-0.3620
|
-0.3750
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/24/22
|
5/10/22
|
8/11/22
|
11/10/22
|
3/23/23
|
5/11/23
|
8/10/23
|
11/14/23
|
3/7/24
|
5/3/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-43.4
|
-44.2
|
-33.4
|
-63.5
|
-45.5
|
-52.8
|
ROE (net income / shareholders' equity)
|
-400%
|
-39.1%
|
-32%
|
-63.2%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-2.320
|
-1.410
|
-0.9100
|
-2.170
|
-1.460
|
-
|
Capex
1 |
-
|
3.61
|
0.77
|
8.43
|
9.75
|
12.3
|
Capex / Sales
|
-
|
22.02%
|
3.86%
|
453.1%
|
81.03%
|
98.72%
|
Announcement Date
|
3/24/22
|
3/23/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
5.05
USD Average target price
12
USD Spread / Average Target +137.62% Consensus |
1st Jan change
|
Capi.
|
---|
| +30.83% | 219M | | +17.96% | 44.96B | | +1.17% | 42.65B | | +47.36% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|